



CONTACT SHEBA MEDICAL CENTER

+972-77-997-2480

GLOBAL PATIENT SERVICES AT SHEBA

- [Our 360 Degree Approach](#)
- [Global Patient Services](#)
- [Why Sheba?](#)
- [Benefits of Treatment at Sheba](#)
- [Meet the Team](#)
- [Patient Stories](#)

USEFUL INFORMATION

- [Find a Doctor](#)
- [The Cancer Center](#)
- [The Rehabilitation Hospital](#)
- [The Children's Hospital](#)
- [Hemato-Oncology Division](#)
- [News](#)
- [General Health Articles](#)
- [Authorized Representative](#)
- [Collaborating with Sheba](#)

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of ALL the cookies. However you may visit [Cookie Settings](#) to provide a controlled con

[Cookie settings](#)

[ACCEPT](#)





The new study about the Pfizer vaccine was published in the peer-reviewed Lancet medical journal

According to a new [Sheba Medical Center](#) study, published in the peer-reviewed Lancet medical journal, COVID-19 infections were reduced by 75% among recipients of the Pfizer-BioNTech

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of ALL the cookies. However you may visit [Cookie Settings](#) to provide a controlled con

[Cookie settings](#)

[ACCEPT](#)



REQUEST A CONSULTATION



"In real life, the data looks at least as good as in the clinical trials, and the first dose is even more effective than we thought," said Prof. Gili Regev-Yochay, Director of the Infectious Diseases Unit at Sheba Medical Center and one of the authors of the study. According to Prof. Eyal Leshem, Director of Sheba's Center for Travel & Tropical Medicine: "This is the first study assessing the efficacy of a single vaccine dose in real-life conditions, and it demonstrates early effectiveness even before the second dose is administered."

Sheba Medical Center is now completing research on the impact of the second dose, which researchers still believe is essential, but according to the study, early reductions of COVID-19 rates provide support for delaying the second dose in countries facing vaccine shortages and scarce resources, so as to allow higher population coverage with a single dose. However, a longer follow-up is required to assess the long-lasting efficacy of a single dose in order to inform a second dose delay policy.

[< Previous](#)

[Next >](#)

Related



We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of ALL the cookies. However you may visit [Cookie Settings](#) to provide a controlled con

[Cookie settings](#)

[ACCEPT](#)



REQUEST A CONSULTATION

News
Main

Dec 06.

NUVO GROUP AND SHEBA DEVELOP AI-POWERED GESTATIONAL DIABETES MANAGEMENT PLATFORM

A groundbreaking gestational diabetes pilot was recently completed by the two organizations, deploying Nuvo's INVU platform at Sheba's Beyond Virtual Hospital, simplifying care for pregnant...

[Read More](#)
News
Main

Dec 01.

BREAKTHROUGH STUDY: RADIATION THERAPY EFFECTIVE FOR PAIN MANAGEMENT IN CANCER PATIENTS

Pancreatic cancer, the 12th most common cancer worldwide, is associated with pain in approximately 75% of patients at the time of diagnosis, and as much...

[Read More](#)

News

Nov 30.

REAL-TIME DETECTION OF CANCEROUS BIOMARKERS WITH ARTIFICIAL INTELLIGENCE

Lung cancer is the most common cancer and accounts for 1.76 million deaths per year worldwide. Non-small cell lung cancer (NSCLC) comprises 85% of all...

[Read More](#)

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of ALL the cookies. However you may visit [Cookie Settings](#) to provide a controlled con

[Cookie settings](#)
[ACCEPT](#)
